Rezolute, Inc. (RZLT) Market Cap
Rezolute, Inc. has a market capitalization of —.
No quote data available.
CEO: Nevan Charles Elam
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2013-01-14
Website: https://www.rezolutebio.com
Rezolute, Inc. (RZLT) - Company Information
Market Cap: -|Sector: Healthcare
Company Profile
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Analyst Sentiment
From 10 Active Polls
1Y Forecast: $8.67
▲ +0.0% Potential Upside
Consensus Target Metrics
Low Bound
$6
Median
$6
High Bound
$14
Average
$9
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
Sentiment volume allocation data unavailable.
Historical valuation matrix unavailable.
Related Companies in Healthcare
📊 AI Financial Analysis
Powered by StockMarketInfo"RZLT reported a pre-revenue quarter: Revenue was $0 and net income was -$16.17M (EPS -$0.16) in 2026-03-31. YoY net income improved (loss narrowed) versus 2025-03-31 (-$18.91M), a ~14.4% reduction in the loss. QoQ, the loss also narrowed versus 2025-12-31 (-$22.77M), an ~29.0% improvement. Operating results show continued cost pressure: R&D was -$11.41M and G&A was -$5.95M, but operating income improved to +$1.20M, driven by a large offset in other income/expense lines (total other income/expenses net of -$17.37M). Over the four-quarter period, profitability remains negative at the bottom line (net losses persist), with EPS losses easing sequentially from the most severe period. Cash flow quality is the key signal right now. Operating cash flow was -$13.74M and free cash flow was -$13.74M. The company continues investing heavily in maturities/purchases of investments, keeping ending cash relatively stable at $11.24M. With no dividends and no buybacks in the quarter, shareholder return is dominated by price action: the stock is up 31.06% over the last year and 59.45% YTD, indicating strong capital appreciation despite persistent operating losses."
Revenue Growth
Revenue was $0 in the most recent quarter and in all comparison periods provided; YoY/QoQ growth is not meaningful.
Profitability
Net income loss narrowed YoY by ~14.4% (-$16.17M vs -$18.91M) and improved QoQ by ~29.0% (-$16.17M vs -$22.77M). However, the company remains loss-making with EPS -$0.16.
Cash Flow Quality
Operating cash flow was -$13.74M and free cash flow -$13.74M. No dividends or buybacks; cash stability appears driven by investment activity rather than operating profitability.
Leverage & Balance Sheet
Balance sheet shows strong liquidity: cash + short-term investments were ~$120.27M. Total assets were $125.46M vs $138.63M QoQ; equity remains sizable at $116.83M, suggesting resilience.
Shareholder Returns
Share price appreciation is strong: +31.06% over 1Y and +59.45% YTD. No dividend yield and no buybacks in the quarter, so total return is primarily price-driven.
Analyst Sentiment & Valuation
Price is $3.46 vs consensus target $6.33 (upside implied), but wide target range ($2–$20) indicates uncertainty typical for pre-commercial/pre-revenue names.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.